Editorial: Vitiligo: from obscurity to spotlight – Advancing care with new therapies and AI

For a long time, vitiligo sat in what one might call the medical blind spot: too visible on the skin to ignore, yet strangely invisible in research budgets. (1) It was easy to dismiss as "cosmetic," to reassure patients with vague platitudes, and to move on to diseases that looked more serious on grant applications. Over the last decade, that posture has become increasingly untenable. If you follow the molecules, the data, and the patient storiesrather than the shifting social media optics -you see a field undergoing a genuine shift. This Research Topic, "Vitiligo: From Obscurity to Spotlight -Advancing Care with New Therapies and AI," was launched in September 2024 to capture that moment. Our aim as Topic Editors was not to curate a glossy showcase of the latest buzzwords, but to bring together work that actually moves the needle: on therapies, on quality of life, on digital tools, and on the lived experience of people with vitiligo.Since launch, the Topic has attracted 21 submissions. After peer review, eight manuscripts were rejected, giving a rejection rate of approximately 40%. In other words, this collection is not a transcript of everything that arrived in our inbox; it is a filtered snapshot of where evidence, methods, and clinical relevance aligned. Finally, "Advancing Vitiligo Care in Russia: Landscape, Lessons, and a Scalable Digital Health Strategy" proposes a coordinated national approach combining teledermatology, electronic records, and AI-enabled workflows to expand access across a geographically distributed population. (5) The paper also highlights locally developed therapeutics (including sodium acridone acetate(6)), illustrating how potentially useful regional practices can remain underrepresented internationally without the infrastructure and incentives required for broader evaluation.More broadly, it is a reminder that some promising therapeutic approaches stay confined to regional practice -not because they lack merit, but because international validation, multicenter trials, and regulatory pathways are costly and complex.Across these contributions, the unifying question is not whether the technology can be built, but whether it can be deployed in a way that improves access, measurement, continuity of care, and ultimately outcomes.Another strong axis of the Topic is the quantification and narration of the patient experience. Two original research articles from Romania -"Comprehensive Analysis Of Life Quality Of Patients With Vitiligo in Romania: insights from a multivariate approach" and "Evaluation of the Clinical and Sociodemographic Features Of Patients With Vitiligo From The Central Region Of Romania" -connect clinical variables to real-world burden, showing how disease extent, duration, and social context intersect to shape quality of life. (7,8) Complementing these quantitative views are three patient-centered opinion pieces.-"Understanding Vitiligo Through the Eyes of a Typical Patient in the U.S." walks the reader through what an "ordinary" journey actually feels like in a high-income healthcare systemdelays, mixed messages, self-experimentation, and the constant negotiation between treatment fatigue and hope.( 9) -"Mapping the Vitiligo Patient Journey: From Awareness to Treatment or Coping Strategies" zooms out to identify key transition points and decision nodes along that journey.( 10) -"Vitiligo: a Call for Paradigm Shift Towards Comprehensive Patient Care" argues for longterm planning that includes comorbidity awareness and psychological support, not only lesion-focused procedures. (11) Together, these papers reinforce a practical point: improved therapies are necessary, but they are not sukicient if access, education, continuity, and psychosocial support remain inconsistent.Therapeutic innovation appears in this Topic through "Injectable Crosslinked HA Hydrogel: A Promising Carrier for Cell Transplantation to Treat Stable Vitiligo," which illustrates how biomaterials may support regenerative and cell-based strategies in appropriately selected patients. (12) This contribution is also a reminder that vitiligo care is unlikely to converge on a single universal solution. Durable progress will likely be plural and combination-basedintegrating topical agents, systemic therapies, phototherapy, surgery, and regenerative approaches in tailored regimens rather than relying on a single "one-size-fits-all" mechanism.Vitiligo does not exist in a social vacuum, and neither does vitiligo research. Two Opinion articles examine World Vitiligo Day (WVD) as both a patient-led movement and a mechanism for sustained change.( 13 The broader implication is that visibility matters most when it builds durable structuresregistries, centers of expertise, patient organizations, and reproducible care pathways.Across themes, three messages recur.First, vitiligo is increasingly understood as a chronic, immune-mediated disease with meaningful clinical and psychosocial consequences, requiring longitudinal care models rather than episodic, lesion-only interventions.Second, AI and digital tools are advancing rapidly, but their value depends on validation, measurement discipline, and thoughtful implementation, not terminology.Third, the greatest impact emerges at the intersection of therapies, digital infrastructure, and patient-centered systems: when ekective treatments reach patients through pathways shaped by accurate information, appropriate triage and monitoring, and supportive communities.This can be conceptualized as a three-layer framework: (i) therapies and regenerative approaches; (ii) digital and AI infrastructure; and (iii) patient journey and advocacy. Where these layers overlap lies the practical goal of durable and equitable improvement in outcomes for people living with vitiligo.As Topic Editors, we are grateful to the authors, reviewers, and readers who contributed to this collection. Our hope is that "Vitiligo: From Obscurity to Spotlight -Advancing Care with New Therapies and AI" will serve not only as a record of where the field stands today, but as a reminder of what still needs to be done.Vitiligo has entered the spotlight. The next task is to ensure that increased attention translates into clarity-about therapies, about tools, and about the care structures that enable people with vitiligo not merely to cope, but to live well.